Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
24 July, 2017 04:13 IST
Glenmark Pharma secures USFDA nod for Clobetasol Propionate ointment
Source: IRIS | 21 Mar, 2017, 09.44AM
Comments  |  Post Comment

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Ointment USP, 0.05%, the generic version of Temovate Ointment, 0.05% of Fougera Pharmaceuticals Inc.

According to IMS Health sales data for the 12 month period ending January 2017, the Temovate Ointment, 0.05% market1 achieved annual sales of approximately USD 175.3 million.

Glenmark's current portfolio consists of 113 products authorized for distribution in the U.S. marketplace and approximately 64 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark (Q,N,C,F)* continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of the company gained Rs 0.9, or 0.1%, to trade at Rs 881.25. The total volume of shares traded was 6,211 at the BSE (9.35 a.m., Tuesday).

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer